Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Provectus Biopharmaceuticals's total assets was $1.47M at Jun 30, 2026. For fiscal 2025 it was $697.50K, down 30.7% from the year before. Over ten years it grew -28.7% a year on average. The highest annual figure on record is $26.18M in fiscal 2014.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $697.50K | -30.7% |
| FY2024 | Dec 31, 2024 | $1.01M | -30.5% |
| FY2023 | Dec 31, 2023 | $1.45M | -28.9% |
| FY2022 | Dec 31, 2022 | $2.04M | -42.0% |
| FY2021 | Dec 31, 2021 | $3.51M | +496.3% |
| FY2020 | Dec 31, 2020 | $589.20K | -60.1% |
| FY2019 | Dec 31, 2019 | $1.48M | -25.7% |
| FY2018 | Dec 31, 2018 | $1.99M | -42.1% |
| FY2017 | Dec 31, 2017 | $3.44M | -38.8% |
| FY2016 | Dec 31, 2016 | $5.61M | -72.5% |
| FY2015 | Dec 31, 2015 | $20.44M | -21.9% |
| FY2014 | Dec 31, 2014 | $26.18M | +30.9% |
| FY2013 | Dec 31, 2013 | $20.01M | +222.5% |
| FY2012 | Dec 31, 2012 | $6.20M | -53.5% |
| FY2011 | Dec 31, 2011 | $13.35M | -7.3% |
| FY2010 | Dec 31, 2010 | $14.40M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.47M | +104.0% |
| Q1 FY2026 | Mar 31, 2026 | $577.58K | -13.3% |
| Q4 FY2025 | Dec 31, 2025 | $697.50K | -30.7% |
| Q3 FY2025 | Sep 30, 2025 | $419.90K | -47.6% |
| Q2 FY2025 | Jun 30, 2025 | $722.38K | -15.7% |
| Q1 FY2025 | Mar 31, 2025 | $666.26K | -38.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.01M | -30.5% |
| Q3 FY2024 | Sep 30, 2024 | $802.03K | -52.5% |
| Q2 FY2024 | Jun 30, 2024 | $856.43K | -49.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.08M | -37.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.45M | -28.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.69M | -17.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.69M | -31.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.72M | -37.6% |
| Q4 FY2022 | Dec 31, 2022 | $2.04M | -42.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.05M | +241.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.44M | +424.0% |
| Q1 FY2022 | Mar 31, 2022 | $2.76M | +257.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.51M | +496.3% |
| Q3 FY2021 | Sep 30, 2021 | $600.34K | -55.4% |
| Q2 FY2021 | Jun 30, 2021 | $466.30K | -74.6% |
| Q1 FY2021 | Mar 31, 2021 | $771.42K | -5.9% |
| Q4 FY2020 | Dec 31, 2020 | $589.20K | -60.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.34M | -14.0% |
| Q2 FY2020 | Jun 30, 2020 | $1.84M | -32.4% |
| Q1 FY2020 | Mar 31, 2020 | $819.96K | -77.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.48M | -25.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.56M | -35.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.72M | -22.9% |
| Q1 FY2019 | Mar 31, 2019 | $3.69M | +20.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.99M | -42.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.42M | -37.1% |
| Q2 FY2018 | Jun 30, 2018 | $3.53M | -28.5% |
| Q1 FY2018 | Mar 31, 2018 | $3.06M | -32.2% |
| Q4 FY2017 | Dec 31, 2017 | $3.44M | -38.8% |
| Q3 FY2017 | Sep 30, 2017 | $3.85M | -63.9% |
| Q2 FY2017 | Jun 30, 2017 | $4.93M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.51M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.61M | – |
| Q3 FY2016 | Sep 30, 2016 | $10.69M | – |
See a number that looks wrong?